HIV Non Occupational Post-Exposure Prophylaxis (PEP)

Phase 4 Completed 100 enrolled Fenway Community Health Merck Sharp & Dohme LLC · collab

NaSingle-groupOpen-labelPrevention

Summary

This study will evaluate how safe and tolerable a combination of taking three-drugs will be for the purpose of preventing HIV transmission after a high-risk sexual contact exposure in HIV uninfected adults.

Timeline

Start: 2008-02
Primary completion: 2010-03
Completion: 2010-08

Publications

Results Mayer KH, Mimiaga MJ, Gelman M, Grasso C. Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence. J Acquir Immune Defic Syndr. 2012 Apr 1;59(4):354-9. doi: 10.1097/QAI.0b013e31824a03b8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Raltegravir	Other / unclassified	400 mg	Oral
Subject	Tenofovir disoproxil fumarate	Small molecule	300 mg	Oral
Subject	emtricitabine	Other / unclassified	200 mg	Oral

HIV Non Occupational Post-Exposure Prophylaxis (PEP)

Summary

Timeline

Publications

Drugs

Indications